ACCELERATED UPTAKE OF INNOVATIVE HEALTH TECHNOLOGIES- A LITERATURE REVIEW
Author(s)
Cowell W1, Ovseiko P2, Lee J3, Ford G4
1Janssen Inc., High Wycombe, UK, 2John Radcliffe Hospital, Oxford, UK, 3Janssen UK, High Wycombe, UK, 4Oxford Academic Health Science Network, Oxford, UK
OBJECTIVES: The Accelerated Access Review made recommendations to speed up access of patients to innovative technologies (medicines, devices and diagnostics), but evidence on how best to achieve this is not readily available. We conducted a literature review of measures to accelerate uptake of health technologies after regulatory approval. This encompasses identification of markets in which pace of adoption has been reported as an issue, initiatives/mechanisms implemented to overcome delays or to accelerate uptake, and their outcome. METHODS: A systematic search of Embase, Medline, Cochrane and the grey literature published in English in 2011-2016. Combinations of search terms such as ‘health care’, ‘innovation’, ‘uptake’, ‘scheme’ and ‘reimbursement’ were used. Identification of relevant articles and data extraction was performed by two independent reviewers with differences resolved by consensus. The evidence was synthesised using a narrative approach. RESULTS: Thirty-two articles met the inclusion criteria. A wide range of themes emerged, including horizon scanning; price negotiation; health technology assessment consideration of ‘innovation’; managed entry agreements (such as conditional approval and financial risk-share); health service financial flows; and leadership around promotion of evidence-based medicine. The most prevalent theme was conditional access. Many papers described the issues and conceptual solutions, rather than reporting implementation of measures and their outcome. CONCLUSIONS: The evidence base on accelerating innovation uptake is limited, from studies with varied designs and quality, and often specific to individual market and policy contexts. Nevertheless, a wide range of factors limiting uptake of innovative technologies is evident, and numerous potential solutions have been proposed. This suggests that multi-factorial interventions that are market and policy specific with pilot testing are required
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PHP40
Topic
Health Policy & Regulatory, Health Service Delivery & Process of Care
Topic Subcategory
Health Care Research, Health Disparities & Equity, Hospital and Clinical Practices, Pricing Policy & Schemes
Disease
Multiple Diseases